Combination of atezolizumab and pirfenidone in second-line and beyond NSCLC: A phase I/II study. Background: Immune checkpoint inhibitors (ICI) have demonstrated efficacy in a wide variety of cancers.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results